Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 2 - Caught on Camera

"I'm a Garden Designer — Here's How I Approach Changing Up My Garden's Planting in Spring When I Want to Try Something New"

Just because you chose a planting scheme once doesn't mean you're stuck with it forever. However, there are tricks to make the transition work

Livingetc

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

MarketBeat

Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s.

Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What Happens When Big Pharma Meets Big Tech?

As AI bolsters the drug discovery pipeline, the boundaries of pharmaceuticals and technology are becoming increasingly blurred.

International Business Times

Should You Buy the Dip in Eli Lilly Stock Today?

Eli Lilly shares sink as data shows Foundayo trailing Novo’s oral Wegovy. But there’s reason to consider buying LLY shares on the dip today.

Barchart

Eli Lilly and Co Reportedly Close to $2 Billion Acquisition of Kelonia Therapeutics

Eli Lilly is reportedly nearing a $2 billion deal to acquire Kelonia Therapeutics, aiming to expand its cancer treatment portfolio with next-generation therapies.

International Business Times

Indiana, Eli Lilly to partner to bring nuclear power to the state

Nuclear is seen as key to AI energy needs, but it's years away from large-scale viability.

Axios

Read news from The Economist, FT, and more,
with one subscription

FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems

The Independent UK

The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

Barchart

Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

MarketBeat

Foundayo vs Zepbound: How Eli Lilly’s new weight loss pill compares to its injectable

IN FULL

The Independent UK

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly stock rallies as the firm’s oral weight-loss pill, Foundayo, secures FDA approval. Options pricing suggests LLY shares will rip higher over the next three months.

Barchart

US approves new oral weight-loss pill developed by Eli Lilly

Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s Wegovy

The Guardian - US

Foundayo: All you need to know about the newly approved weight-loss pill

The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8B in Sleep Drug Mega-Deal, CNTA Stock Soaring 45%

Shares of Centessa Pharmaceuticals plc skyrocketed more than 44% Tuesday after the clinical-stage biotech announced it would be acquired by pharmaceutical giant Eli Lilly and Co. in a deal valued at up to $7.8 billion, giving Lilly a promising pipeline of experimental treatments for sleep-wake disorders.

Barchart

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

Euronews

Eli Lilly invests in AI-designed drugs in new deal with Insilico Medicine worth up to €2.39bn

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

The Independent UK

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs

Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their benefits “too small” to justify the cost

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day

Pharma exports helped double Ireland’s goods trade surplus with the U.S. to $114 billion last year.

MarketBeat

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

MarketBeat

The Real Reason Eli Lilly Is Pouring $3 Billion Into China

Eli Lilly's major investment in China's manufacturing capacity is a strategic move to secure its supply chain and capture a vast, untapped growth market.

Sports Illustrated

Beyond the Slopes: Mikaela Shiffrin’s Mission to Help Educate Families Facing Early Symptomatic Alzheimer’s Disease

Mikaela was compensated for her time by Eli Lilly and Company. The Most Decorated Skier of Our Time Mikaela Shiffrin knows what it means to chase down a challen

Barchart

Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

Barchart

Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

The Guardian - UK

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Eli Lilly and Company

60 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.